Medication errors related to high-alert medications in a paediatric university hospital - a cross-sectional study analysing error reporting system data.
High-alert medication
Hospital
Medication error
Medication error reporting
Medication management and use process
Medication safety
Paediatrics
Patient safety
Risk management
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
31 10 2023
31 10 2023
Historique:
received:
05
06
2023
accepted:
27
09
2023
medline:
2
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
Paediatric patients are prone to medication errors, and only a few studies have explored errors in high-alert medications in children. The present study aimed to investigate the prevalence and nature of medication errors involving high-alert medications and whether high-alert medications are more likely associated with severe patient harm and higher error risk classification compared to other drugs. This study was a cross-sectional report of self-reported medication errors in a paediatric university hospital in 2018-2020. Medication error reports involving high-alert medications were investigated by descriptive quantitative analysis to identify the prevalence of different drugs, Anatomical Therapeutic Chemical groups, administration routes, and the most severe medication errors. Crosstabulation and Pearson Chi-Square (χ2) tests were used to compare the likelihood of more severe consequences to the patient and higher error risk classification between medication errors involving high-alert medications and other drugs. Among the reported errors (n = 2,132), approximately one-third (34.8%, n = 743) involved high-alert medications (n = 872). The most common Anatomical Therapeutic Chemical subgroups were blood substitutes and perfusion solutions (B05; n = 345/872, 40%), antineoplastic agents (L01; n = 139/872, 16%), and analgesics (N02; n = 98/872, 11%). The majority of high-alert medications were administered intravenously (n = 636/872, 73%). Moreover, IV preparations were administered via off-label routes (n = 52/872, 6%), such as oral, inhalation and intranasal routes. Any degree of harm (minor, moderate or severe) to the patient and the highest risk classifications (IV-V) were more likely to be associated with medication errors involving high-alert medications (n = 743) when compared to reports involving other drugs (n = 1,389). Preventive risk management should be targeted on high-alert medications in paediatric hospital settings. In these actions, the use of intravenous drugs, such as parenteral nutrition, concentrated electrolytes, analgesics and antineoplastic agents, and off-label use of medications should be prioritised. Further research on the root causes of medication errors involving high-alert medications and the effectiveness of safeguards is warranted.
Sections du résumé
BACKGROUND
Paediatric patients are prone to medication errors, and only a few studies have explored errors in high-alert medications in children. The present study aimed to investigate the prevalence and nature of medication errors involving high-alert medications and whether high-alert medications are more likely associated with severe patient harm and higher error risk classification compared to other drugs.
METHODS
This study was a cross-sectional report of self-reported medication errors in a paediatric university hospital in 2018-2020. Medication error reports involving high-alert medications were investigated by descriptive quantitative analysis to identify the prevalence of different drugs, Anatomical Therapeutic Chemical groups, administration routes, and the most severe medication errors. Crosstabulation and Pearson Chi-Square (χ2) tests were used to compare the likelihood of more severe consequences to the patient and higher error risk classification between medication errors involving high-alert medications and other drugs.
RESULTS
Among the reported errors (n = 2,132), approximately one-third (34.8%, n = 743) involved high-alert medications (n = 872). The most common Anatomical Therapeutic Chemical subgroups were blood substitutes and perfusion solutions (B05; n = 345/872, 40%), antineoplastic agents (L01; n = 139/872, 16%), and analgesics (N02; n = 98/872, 11%). The majority of high-alert medications were administered intravenously (n = 636/872, 73%). Moreover, IV preparations were administered via off-label routes (n = 52/872, 6%), such as oral, inhalation and intranasal routes. Any degree of harm (minor, moderate or severe) to the patient and the highest risk classifications (IV-V) were more likely to be associated with medication errors involving high-alert medications (n = 743) when compared to reports involving other drugs (n = 1,389).
CONCLUSIONS
Preventive risk management should be targeted on high-alert medications in paediatric hospital settings. In these actions, the use of intravenous drugs, such as parenteral nutrition, concentrated electrolytes, analgesics and antineoplastic agents, and off-label use of medications should be prioritised. Further research on the root causes of medication errors involving high-alert medications and the effectiveness of safeguards is warranted.
Identifiants
pubmed: 37907939
doi: 10.1186/s12887-023-04333-2
pii: 10.1186/s12887-023-04333-2
pmc: PMC10617051
doi:
Substances chimiques
Analgesics
0
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
548Informations de copyright
© 2023. The Author(s).
Références
Pediatrics. 2021 Sep;148(3):
pubmed: 34408092
Drug Saf. 2022 Jan;45(1):1-18
pubmed: 34932206
Expert Opin Drug Saf. 2013 Nov;12(6):805-14
pubmed: 23931332
Drug Saf. 2019 Nov;42(11):1329-1342
pubmed: 31290127
Pharmacoepidemiol Drug Saf. 2007 Sep;16(9):1006-13
pubmed: 17523185
BMC Med Inform Decis Mak. 2011 Feb 21;11:14
pubmed: 21338518
BMJ. 2000 Mar 18;320(7237):768-70
pubmed: 10720363
Cancer. 2007 Jul 1;110(1):186-95
pubmed: 17530619
Pediatr Crit Care Med. 2009 Jan;10(1):85-90
pubmed: 19057440
Drug Saf. 2019 Dec;42(12):1423-1436
pubmed: 31410745
BMJ. 2019 Jul 17;366:l4185
pubmed: 31315828
Eur J Pediatr. 2017 Dec;176(12):1697-1705
pubmed: 28965285
J Pediatr Pharmacol Ther. 2012 Apr;17(2):166-72
pubmed: 23118669
Am J Health Syst Pharm. 2018 Aug 1;75(15):1151-1165
pubmed: 29555640
BMC Pediatr. 2022 Mar 8;22(1):118
pubmed: 35255846
Res Social Adm Pharm. 2019 Jul;15(7):864-872
pubmed: 30509853
Pediatrics. 2018 Dec;142(6):
pubmed: 30478247
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
Eur J Hosp Pharm. 2021 Nov;28(Suppl 2):e56-e61
pubmed: 32576572
J Patient Saf. 2021 Dec 1;17(8):e1669-e1680
pubmed: 32175962
J Patient Saf. 2020 Jun;16(2):168-176
pubmed: 27010325
P T. 2016 Oct;41(10):598-600
pubmed: 27756996
BMC Pediatr. 2019 Dec 11;19(1):486
pubmed: 31829142
JAMA. 2001 Apr 25;285(16):2114-20
pubmed: 11311101
J Eval Clin Pract. 2015 Apr;21(2):262-70
pubmed: 25560989
Pediatrics. 2019 Feb;143(2):
pubmed: 30670581
J Patient Saf. 2021 Sep 1;17(6):417-424
pubmed: 28574956
Eur J Clin Nutr. 2021 Jan;75(1):3-11
pubmed: 32523089
BMJ Paediatr Open. 2020 Dec 30;4(1):e000880
pubmed: 33437879
Acta Paediatr. 2020 Dec;109(12):2810-2819
pubmed: 32239536
Clin Nutr. 2018 Dec;37(6 Pt B):2392-2400
pubmed: 30061055
Pharmazie. 2022 Jun 1;77(6):207-215
pubmed: 35751160
J Perinatol. 2010 Jul;30(7):459-68
pubmed: 20043010